BioNxt Solutions (TSE:BNXT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioNxt Solutions is developing a sublingual thin-film for Semaglutide, aiming to improve patient accessibility and convenience by overcoming the limitations of injectable formats. This innovative delivery system promises rapid absorption and enhanced bioavailability, potentially transforming diabetes and obesity treatment.
For further insights into TSE:BNXT stock, check out TipRanks’ Stock Analysis page.